Compare DSL & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSL | AMPH |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2013 | 2005 |
| Metric | DSL | AMPH |
|---|---|---|
| Price | $10.98 | $20.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | ★ 646.2K | 453.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 12.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.03 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $4.76 |
| P/E Ratio | ★ N/A | $10.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.49 | $17.03 |
| 52 Week High | $12.67 | $31.26 |
| Indicator | DSL | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 49.93 |
| Support Level | $10.89 | $20.41 |
| Resistance Level | $11.45 | $29.30 |
| Average True Range (ATR) | 0.15 | 0.68 |
| MACD | 0.05 | 0.42 |
| Stochastic Oscillator | 79.51 | 84.73 |
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.